New data from observational studies in the UK shows that patients with type 2 diabetes experience greater reduction of HbA1c levels when using Victoza compared to Byetta (exenatide) and DPP-4 inhibitors. Victoza...
Sanofi has presented data from two studies demonstrating Lyxumia (lixisenatide), a once-daily investigational GLP-1 agonist, in combination with basal insulin plus oral anti-diabetic agents (OADs), significantly reduced HbA1c levels...
Nine years ago my relationship with diabetes began with the words, “You know that you have diabetes, right?”
Today I find myself reflecting and…
I’m live-blogging from the 2012 ADA Scientific Sessions in Philadelphia. Here’s coverage from Day 1 and Day 2, including an update…
Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta(TM), the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited...
Biodel Inc. has partnered with Aegis Therapeutics, LLC (Aegis) and has obtained exclusive worldwide license to Aegis' proprietary ProTek and Intravail technologies for the development and commercialization of pharmaceutical formulations of glucagon...
I’m at the 2012 ADA Scientific Sessions and am keeping a live blog about my experiences (here’s a link to my day 1 coverage of the ADA…
Tandem announced today, at the 72nd Scientific Sessions of the American Diabetes Association, that it will begin accepting orders for the t:slimTM Insulin Delivery System, the first insulin pump approved by the FDA with a touch screen...
In the next step toward the development of an artificial pancreas, Medtronic announced that it has filed the final module of its Pre-Market Approval (PMA) application with the U.S. Food and Drug Administration for the MiniMed 530G system featuring Threshold Suspend Automation. If approved...